Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cross-sectional Population-based HIV Impact Assessment surveys.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
13
07
2021
revised:
20
10
2021
accepted:
27
10
2021
entrez:
5
2
2022
pubmed:
6
2
2022
medline:
15
3
2022
Statut:
ppublish
Résumé
In 2020, there were an estimated 1·7 million children younger than 15 years living with HIV worldwide, but there are few data on the proportion of children living with HIV who are undiagnosed. We aimed to estimate the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe. We conducted an analysis of data from the cross-sectional Population-based HIV Impact Assessment (PHIA) surveys from 2015 to 2017. PHIAs are nationally representative surveys measuring HIV outcomes. HIV rapid test data (with PCR confirmatory testing for children aged <18 months) were used to measure HIV prevalence among children in each country (Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe). Mothers or guardians reported previous HIV testing of children and previous results. Detection of antiretroviral medications was done using dried blood spots. Children who tested positive in the PHIA with previous negative or unknown HIV test results and without detectable antiretroviral medication blood concentrations were considered previously undiagnosed; all other children who tested positive were considered previously diagnosed. Survey weights with jackknife variance were used to generate national estimates of HIV prevalence and undiagnosed HIV in children aged 1-14 years. We also report the prevalence (weighted proportions) of antiretroviral therapy coverage and viral load suppression (<400 copies per mL). Between 2015 and 2017, 42 248 children aged 1-14 years were included in the surveys, of whom 594 were living with HIV. Across the seven countries, the estimated weighted HIV prevalence was 0·9% (probability band 0·7-1·1) and we estimated that there were 425 000 (probability band 365 000-485 000) children living with HIV. Among all children living with HIV, 61·0% (n=259 000 [probability band 216 000-303 000]) were previously diagnosed and 39·0% (n=166 000 [128 000-204 000]) had not been previously diagnosed with HIV. Among previously diagnosed children living with HIV, 88·4% had detectable antiretroviral medication blood concentrations and 48·3% had viral load suppression. Among all children living with HIV (regardless of previous diagnosis status), 54·7% had detectable antiretroviral medication blood concentrations and 32·6% had viral load suppression. Our findings show the uneven coverage of paediatric HIV testing across these seven countries and underscore the urgent need to address gaps in diagnosis and treatment for all children living with HIV. None.
Sections du résumé
BACKGROUND
In 2020, there were an estimated 1·7 million children younger than 15 years living with HIV worldwide, but there are few data on the proportion of children living with HIV who are undiagnosed. We aimed to estimate the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe.
METHODS
We conducted an analysis of data from the cross-sectional Population-based HIV Impact Assessment (PHIA) surveys from 2015 to 2017. PHIAs are nationally representative surveys measuring HIV outcomes. HIV rapid test data (with PCR confirmatory testing for children aged <18 months) were used to measure HIV prevalence among children in each country (Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe). Mothers or guardians reported previous HIV testing of children and previous results. Detection of antiretroviral medications was done using dried blood spots. Children who tested positive in the PHIA with previous negative or unknown HIV test results and without detectable antiretroviral medication blood concentrations were considered previously undiagnosed; all other children who tested positive were considered previously diagnosed. Survey weights with jackknife variance were used to generate national estimates of HIV prevalence and undiagnosed HIV in children aged 1-14 years. We also report the prevalence (weighted proportions) of antiretroviral therapy coverage and viral load suppression (<400 copies per mL).
FINDINGS
Between 2015 and 2017, 42 248 children aged 1-14 years were included in the surveys, of whom 594 were living with HIV. Across the seven countries, the estimated weighted HIV prevalence was 0·9% (probability band 0·7-1·1) and we estimated that there were 425 000 (probability band 365 000-485 000) children living with HIV. Among all children living with HIV, 61·0% (n=259 000 [probability band 216 000-303 000]) were previously diagnosed and 39·0% (n=166 000 [128 000-204 000]) had not been previously diagnosed with HIV. Among previously diagnosed children living with HIV, 88·4% had detectable antiretroviral medication blood concentrations and 48·3% had viral load suppression. Among all children living with HIV (regardless of previous diagnosis status), 54·7% had detectable antiretroviral medication blood concentrations and 32·6% had viral load suppression.
INTERPRETATION
Our findings show the uneven coverage of paediatric HIV testing across these seven countries and underscore the urgent need to address gaps in diagnosis and treatment for all children living with HIV.
FUNDING
None.
Identifiants
pubmed: 35120641
pii: S2352-3018(21)00291-5
doi: 10.1016/S2352-3018(21)00291-5
pmc: PMC10350876
mid: NIHMS1905885
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
e91-e101Subventions
Organisme : CGH CDC HHS
ID : U2G GH001226
Pays : United States
Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
AIDS. 2019 Jul 1;33(8):1391-1395
pubmed: 30950882
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):427-438
pubmed: 29287029
Clin Infect Dis. 2016 Dec 15;63(12):1645-1654
pubmed: 27660236
J Antimicrob Chemother. 2017 Feb;72(2):365-371
pubmed: 27999070
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S88-S97
pubmed: 29994830
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S6-S16
pubmed: 34166308
BMJ Open. 2019 Jul 29;9(7):e024907
pubmed: 31362959
J Int AIDS Soc. 2019 Apr;22(4):e25271
pubmed: 30958644
Glob Pediatr Health. 2021 Mar 23;8:2333794X211003622
pubmed: 33816712
J Int AIDS Soc. 2018 Aug;21(8):e25168
pubmed: 30094952
PLoS One. 2021 Mar 5;16(3):e0247974
pubmed: 33667258
N Engl J Med. 2008 Nov 20;359(21):2233-44
pubmed: 19020325
Pediatr Infect Dis J. 2017 Jun;36(6):595-601
pubmed: 28027287
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S134-S141
pubmed: 29994836
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S17-S27
pubmed: 34166309
Lancet HIV. 2016 Oct;3(10):e473-81
pubmed: 27658876
PLoS Med. 2018 Mar 30;15(3):e1002547
pubmed: 29601570
Lancet HIV. 2019 Jun;6(6):e373-e381
pubmed: 30987937
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
Pediatr Infect Dis J. 2020 Dec;39(12):1101-1102
pubmed: 32925541
J Int AIDS Soc. 2015 Oct 14;18:20182
pubmed: 26471265
AIDS Behav. 2021 Aug;25(8):2419-2429
pubmed: 33709212
PLoS Med. 2014 May 27;11(5):e1001650
pubmed: 24866364
Trop Med Int Health. 2017 Aug;22(8):1021-1029
pubmed: 28544728
Curr Pediatr Rep. 2015 Sep;3(3):219-229
pubmed: 26709366